DekaBank Deutsche Girozentrale lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 70,119 shares of the biopharmaceutical company’s stock after selling 5,056 shares during the period. DekaBank Deutsche Girozentrale owned 0.07% of Regeneron Pharmaceuticals worth $32,989,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the company. FMR LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after purchasing an additional 416,192 shares during the period. BlackRock Inc. lifted its holdings in Regeneron Pharmaceuticals by 0.7% in the second quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock valued at $3,039,305,000 after buying an additional 41,406 shares during the period. Vanguard Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 2.9% in the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock valued at $2,588,533,000 after buying an additional 148,962 shares during the period. Artisan Partners Limited Partnership lifted its holdings in Regeneron Pharmaceuticals by 1.5% in the second quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock valued at $963,852,000 after buying an additional 29,252 shares during the period. Finally, Polen Capital Management LLC lifted its holdings in Regeneron Pharmaceuticals by 7.3% in the second quarter. Polen Capital Management LLC now owns 1,586,320 shares of the biopharmaceutical company’s stock valued at $779,105,000 after buying an additional 108,413 shares during the period. Institutional investors own 67.80% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/11/14/dekabank-deutsche-girozentrale-sells-5056-shares-of-regeneron-pharmaceuticals-inc-regn.html.
In other Regeneron Pharmaceuticals news, SVP Robert E. Landry sold 468 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $476.45, for a total value of $222,978.60. Following the transaction, the senior vice president now directly owns 9,099 shares in the company, valued at $4,335,218.55. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares in the company, valued at $5,060,204.94. The disclosure for this sale can be found here. Over the last quarter, insiders sold 88,942 shares of company stock worth $42,064,076. Corporate insiders own 10.80% of the company’s stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded down $10.92 on Tuesday, reaching $393.62. 1,417,500 shares of the company’s stock were exchanged, compared to its average volume of 902,722. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $43,346.87, a PE ratio of 35.03, a price-to-earnings-growth ratio of 1.56 and a beta of 1.56. Regeneron Pharmaceuticals, Inc. has a 52-week low of $340.09 and a 52-week high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period in the previous year, the company earned $3.13 earnings per share. sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.77 EPS for the current year.
REGN has been the topic of several recent analyst reports. J P Morgan Chase & Co restated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 31st. Barclays PLC lowered shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and dropped their target price for the company from $450.00 to $395.00 in a report on Friday, October 20th. Guggenheim restated a “buy” rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Morgan Stanley restated an “equal weight” rating and issued a $490.00 target price (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Finally, BMO Capital Markets restated a “market perform” rating and issued a $484.00 target price (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $481.49.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.